KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Current Liabilities (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Total Current Liabilities for 16 consecutive years, with $4.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 17.25% year-over-year to $4.9 million, compared with a TTM value of $4.9 million through Sep 2025, down 17.25%, and an annual FY2024 reading of $5.2 million, down 24.63% over the prior year.
  • Total Current Liabilities was $4.9 million for Q3 2025 at TherapeuticsMD, up from $4.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $264.8 million in Q1 2022 and bottomed at $4.7 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $66.9 million, with a median of $16.9 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities soared 332.14% in 2022, then plummeted 92.7% in 2023.
  • Year by year, Total Current Liabilities stood at $252.9 million in 2021, then tumbled by 81.48% to $46.8 million in 2022, then plummeted by 85.37% to $6.9 million in 2023, then dropped by 24.63% to $5.2 million in 2024, then dropped by 4.28% to $4.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for TXMD at $4.9 million in Q3 2025, $4.7 million in Q2 2025, and $4.7 million in Q1 2025.